SCHEMBL20319075

SCHEMBL20319075

CBc1cccc(-c2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ MGLL Q99685 3/20 0.40
▸ HDAC8 Q9BY41 2/20 0.39
▸ KMO O15229 1/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ ALOX5 P09917 1/20 0.38
▸ PRSS1 P07477 1/20 0.38
▸ PRSS2 P07478 1/20 0.38
▸ PRSS3 P35030 1/20 0.38
▸ AGXT P21549 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ HSD17B1 P14061 1/20 0.36
▸ HSD17B2 P37059 1/20 0.36
▸ SLC22A2 O15244 1/20 0.36
▸ SLC22A1 O15245 1/20 0.36
▸ SLC22A3 O75751 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14653450 0.84 MEN1 (0.44) MAOAALDH1A1MGLLKMOALOX5
SCHEMBL19526717 0.82 MEN1 (0.47) ALDH1A1MEN1KMT2APKMATM
SCHEMBL14644147 0.81 TRIM58 (0.33) CYP3A4CYP2C9HSD17B1HSD17B2MEN1
SCHEMBL21389008 0.81 ALDH1A1 (0.43) ALDH1A1ALOX5CYP3A4SLC22A2SLC22A1
SCHEMBL19833162 0.80 MAOA (0.48) MAOAALDH1A1MGLLHDAC8KMO
SCHEMBL13140628 0.79 ACHE (0.35) —
SCHEMBL14492415 0.77 ALDH1A1 (0.50) ALDH1A1MGLLALOX5CYP3A4SLC22A2
SCHEMBL14643579 0.77 ALDH1A1 (0.50) ALDH1A1MGLLALOX5CYP3A4SLC22A2
SCHEMBL10263396 0.76 MGLL (0.45) MAOAALDH1A1MGLLHDAC8KMO
SCHEMBL274934 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 — — US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 MAOA 928/4885ALDH1A1 122/4885MGLL 1703/4885
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 MAOA 928/4885ALDH1A1 122/4885MGLL 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback